Innovus Pharmaceuticals signs license and distribution agreement with Luminarie

Female Sexual Dysfunction is estimated to affect 43 percent of women in the U.S. between 18 and 59.
Female Sexual Dysfunction is estimated to affect 43 percent of women in the U.S. between 18 and 59. | File photo

Innovus Pharmaceuticals Inc. is signing an exclusive license and distribution agreement for commercialization of Zestra and Zestra Glide with Luminarie Pty Ltd. throughout Australia, New Zealand and the Philippines.

Zestra has been developed using a natural mix of oils for the treatment of Female Sexual Arousal Disorder in order to address Female Sexual Dysfunction, which is estimated to affect 43 percent of women in the U.S. between 18 and 59.

Innovus is a specialty pharmaceutical company that focuses on the licensing, development and commercialization of non-prescription medicines that have been proven to be safe and effective, as well as products aimed at improving the health of both men and women in the categories of vitality and respiratory health.

"We are delighted to be working with Innovus Pharma on the commercialization of their Zestra and Zestra Glide products into Australia, New Zealand and the Philippines," Luminarie CEO Hermant Gulhant said, adding that the company believes all of the products would be welcomed in the new countries.

Zestra is approved in more than 28 countries.

"Luminaire is now our 16th distribution partner for our products outside the United States and we look forward to expanding our sales into these important countries with them," Innovus Pharma CEO Dr. Bassam Damaj said.

Want to get notified whenever we write about Innovus Pharmaceuticals, Inc. ?
Next time we write about Innovus Pharmaceuticals, Inc., we'll email you a link to the story. You may edit your settings or unsubscribe at any time.
Organizations in this story

Innovus Pharmaceuticals, Inc. 9171 Towne Centre Dr San Diego, CA - 92122